NEW YORK (GenomeWeb) – Second Genome today announced it has entered into a research alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC) in Ireland.

The partners said they will develop therapies to prevent and treat inflammatory bowel disease (IBD) based on the role of the microbiome. To do so, they will analyze data from patients to find new opportunities for treatment. Second Genome has developed a drug discovery platform that integrates microbiome and host biology, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.